Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
A recently published article (Rational Pharmacotherapy in Cardiology 2018;6:908-16) on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomize...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Столичная издательская компания,
2019-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A recently published article (Rational Pharmacotherapy in Cardiology 2018;6:908-16) on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized controlled trials (RCTs) with NOAC (except for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail patients; 2) one of the studies of real clinical practice showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk of stroke / systemic embolism and ischemic stroke in frail elderly patients with atrial fibrillation after 2 years of observation. The paper presents a critical analysis of these statements showing that the first statement is based on the incorrect use of the collective term "fragility" as a synonym for the term "frailty", whereas the second statement is based on the results of a study that has a number of serious methodological limitations. |
|---|---|
| Item Description: | 1819-6446 2225-3653 |